Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma

Ceresoli, Giovanni Luca; Zucali, Paolo Andrea; Favaretto, Adolfo; Grossi, Francesco; Bidoli, Paolo; Conte, Guido Del; Anna, Ceribelli; Bearz, Alessandra; Morenghi, Emanuela; Cavina, Raffaele; Marangolo, M.; Parra, Héctor Soto; Santoro, Armando

doi:10.1200/jco.2005.04.3190

Cited by 268 publications

(176 citation statements)

References 29 publications

Supporting

Mentioning

160

Contrasting

Unclassified

Order By: Relevance

“…At present, as cases of malignant mesothelioma of the tunica vaginalis testis are rare, radiation and chemotherapy for malignant testicular mesothelioma remain controversial. Cisplatin and pemetrexed may be used as chemotherapy for testicular mesothelioma (21). In the present case, pemetrexed and cisplatin were administered at a dose of 900 and 130 mg, respectively, on the first day of a 28-day cycle for a total of six chemotherapy cycles.…”

Section: Discussionmentioning

confidence: 99%

Malignant mesothelioma of the tunica vaginalis testis: A case report and literature review

Zhang

et al. 2017

mol clin onc

View full text Add to dashboard Cite

Abstract. Malignant mesothelioma of the tunica vaginalis testis is an extremely rare tumor without specific clinical manifestations, mainly including hydrocele formation and a painless mass. We herein present the case of a patient with hydrocele of the left testis, without any other complaints. Tunica vaginalis subinvolution was performed, and postoperative pathological examination revealed a malignant mesothelioma arising from the left tunica vaginalis testis. Whole-body positron emission tomography-computed tomography (PET-CT) and subsequent abdominal and pelvic magnetic resonance imaging (MRI) revealed no evidence of local lymphadenopathy. Radical left orchiectomy was performed after the pathological diagnosis. The pathological examination after the second surgery demonstrated that the tumor had invaded the adjacent periorchium and spermatic cord, but there was no evidence of local lymph node metastasis. Pemetrexed and cisplatin were administered at a dose of 900 and 130 mg, respectively, on the first day of a 28-day cycle. After 6 months of therapy, the disease had not progressed on abdominal and pelvic PET-CT and MRI. The patient was still followed up in our urology outpatient clinic at the time of the present report. Although testicular hydrocele is a common and easily diagnosed condition, detailed medical history and physical examination are required. Thus, when clinicians encounter patients with testicular hydrocele, a variety of possible causes must be considered, including testicular or paratesticular tumors, even rare tumors such as mesothelioma of the tunica vaginalis testis.

show abstract

Section: Discussionmentioning

confidence: 99%

Malignant mesothelioma of the tunica vaginalis testis: A case report and literature review

Zhang

et al. 2017

mol clin onc

View full text Add to dashboard Cite

show abstract

“…When comparing carboplatin to cisplatin, the latter is more commonly associated with neutropenia whereas carboplatin is more likely to cause anemia and thrombocytopenia. Outcomes are otherwise similar suggesting that these therapies may be substituted depending on the particular clinical situation [18].…”

Section: Induction Therapy/chemotherapymentioning

confidence: 99%

Malignant Pleural Mesothelioma: Treatment Options and Novel Therapies

Martin¹,

Zwischenberger²,

Fabian³

2014

JCT

View full text Add to dashboard Cite

Malignant pleural mesothelioma is a rare primary tumor rising from the pleura and is associated with exposure to asbestos fibers. Mesothelioma is a locally aggressive disease that usually presents at an advanced stage and has a median overall survival of 1 year. Treatment options rarely result in cure of disease and range from trimodality treatment, including chemotherapy, radiation, and surgery, to supportive care. In patients with limited local disease and good functional status, trimodality treatment with extra-pleural pneumonectomy, chemotherapy, and radiation is frequently employed. Best supportive care should be instituted for patients with metastatic disease and poor functional status. Palliative therapy focuses on control of pleural effusions with drainage techniques and pain with radiation therapy. Novel therapies are showing promise, including photodynamic therapy, immunotherapy, and molecular targeted therapy.

show abstract

“…However, in recent years some evidence suggested that pemetrexed plus cisplatin or carboplatin resulted in superior survival time. [13][14][15] In the present study cohort, a proportion of patients received pemetrexed combined with cisplatin or carboplatin. All patients were followed prospectively at three-monthly intervals for the first year and six-monthly thereafter until the last time of contact or death.…”

Section: Methodsmentioning

confidence: 99%